The Laurus Labs Q2 results are a case study in how product mix can transform profit. For the quarter ended 30 September 2026, the company reported revenue of ₹2,206 crore, up 33%, but net profit of ₹441 crore, up 126%, and EBITDA of ₹762 crore, up 78% at a 34.5% margin. This analysis looks at the segment mix, margin bridge, cash returns and risks behind the numbers, and what the company has and has not disclosed. It reports company figures and press accounts and offers no investment recommendation.
Laurus Labs Q2 results: financial takeaways
- Revenue ₹2,206 crore (+33%); EBITDA ₹762 crore (+78%); net profit ₹441 crore (+126%).
- EBITDA margin 34.5%, about 850 basis points higher; gross margin 63%.
- CDMO ₹904 crore (+75%) against generics ₹1,302 crore (+15%).
- First-half revenue ₹4,233 crore (+31%) and net profit ₹809 crore versus ₹358 crore.
- Interim dividend of ₹1.00 per share; shares closed up 2.75% at ₹2,245 on the BSE.
Segment mix in the Laurus Labs Q2 results
By our own calculation, CDMO made up about 41% of quarterly revenue (₹904 crore of ₹2,206 crore) and the generics business about 59% (₹1,302 crore). In the first half the split was roughly 42% and 58% on the company’s reported figures of ₹1,774 crore and ₹2,459 crore. The faster growth in the smaller segment is shifting the mix towards contract work. Filings are available from BSE.
The margin bridge behind the Laurus Labs Q2 results
A year earlier, revenue was ₹1,653 crore. Revenue therefore rose by roughly ₹553 crore by our own calculation, while net profit rose by ₹246 crore, from ₹195 crore to ₹441 crore. In other words, around 44% of the incremental revenue reached net profit, far above the 12% net margin of the year-earlier quarter (₹195 crore over ₹1,653 crore) and above the 20% net margin of this quarter. That gap indicates strong incremental margins, probably reflecting mix, though the company did not provide a detailed bridge. EBITDA of ₹762 crore on revenue of ₹2,206 crore gives the 34.5% margin.
Sequential and half-year view of the Laurus Labs Q2 results
Net profit rose about 20% from ₹368 crore in the previous quarter. First-half EBITDA was ₹1,406 crore at a 33.2% margin, so the second quarter’s 34.5% was slightly above the half-year average. That suggests the margin is still moving up, although a single quarter is not a trend. The company did not provide guidance in the information we reviewed.
Customer concentration and the Laurus Labs Q2 results
CDMO revenue depends on contracts with a limited number of large customers, and individual projects can start, pause or finish on timelines the CDMO does not control. A strong quarter can therefore reflect the timing of milestones as well as underlying demand. The sources do not name customers or report concentration, so we cannot assess this risk for Laurus. It is nonetheless the first question analysts usually ask when CDMO growth runs at 75%, because lumpy projects can reverse. Readers should look for disclosure of the top customers’ share of revenue and the length of contracts in the company’s investor materials.
Capital allocation and the Laurus Labs Q2 results
Research and development including capital expenditure was ₹183 crore in the first half, 4.3% of revenue. The company commissioned its first commercial-scale peptide plant at Visakhapatnam and plans to acquire 60% of Galenvs Sciences for US$3.75 million in total investment, which is small next to quarterly profit. Chief executive Dr Satyanarayana Chava said Galenvs adds differentiated technology to the TIDES business. Company information is at lauruslabs.com.
Three ways to read the Laurus Labs Q2 results
An optimistic reading is that the mix shift is structural, new peptide and oligonucleotide capacity extends it, and margins hold in the low-to-mid thirties. A cautious reading is that part of the quarter reflects project timing and a low prior-year base, so growth and margins could normalise. A neutral reading is that the quarter confirms the direction of travel but the durability cannot be judged without customer, order book and guidance data. These are framing devices for readers, not forecasts.
Market context from Acumen Research and Consulting
Acumen Research and Consulting’s HPAPI CDMO Market report values that market at USD 9.40 billion in 2025 and projects more than USD 27 billion by 2035, a CAGR of 11.1% for 2026 to 2035. North America accounts for about 38% and Asia Pacific is projected to grow faster, at more than 12.4%. The FAQ’s 2026 value does not fully reconcile with the stated CAGR and the report covers high-potency work only, so it is sector context and not a measure of Laurus’s opportunity.
Questions analysts may ask about the Laurus Labs Q2 results
How much of the margin gain is structural? What is the order book for CDMO? How quickly can the peptide plant contribute? Will generics growth stay in the mid-teens? How concentrated are the largest customers? None of these is answered in the information we reviewed, and this article offers no investment view.
Timeline of the Laurus Labs Q2 results
- 30 September 2026: quarter ends.
- Late October 2026: results and interim dividend announced.
- Same period: Galenvs deal announced, subject to due diligence.
General background: the CDMO business model
CDMOs earn fees for developing and making medicines for clients. Revenue can be stable when contracts are long, but it can also be concentrated among a few customers and sensitive to project timing. See our industry insights.
Our analysis of the Laurus Labs Q2 results
In our assessment, the Laurus Labs Q2 results show unusually strong operating leverage, driven by CDMO mix. The main uncertainty is durability: customer concentration, project timing and the cost of new capacity could all move the margin.
What is not disclosed in the Laurus Labs Q2 results
- Customer concentration.
- Order book and guidance.
- One-off items, if any.
Risks and caveats
This article summarises company results and press accounts. Our calculations are labelled and approximate. It is news reporting and not investment advice.
What to watch next
- Peptide plant ramp-up.
- Galenvs completion.
- Q3 margin trend.
FAQ
What was the net profit?
₹441 crore, up 126%.
What was the EBITDA margin?
34.5%.
What dividend was declared?
An interim dividend of ₹1.00 per share.
How we reported this: we relied on the company’s results announcement as reported, public company pages and the Acumen Research and Consulting report cited above. Our calculations are labelled. Last updated 30 October 2026. This is news reporting and not advice.
